Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mite allergen extract is a biological product used in allergen-specific immunotherapy (AIT) for the treatment of house dust mite (HDM)-induced allergic rhinitis and allergic asthma. It typically consists of a standardized mixture of allergens from the dust mite species *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. The mechanism involves modulating the patient's immune system to induce allergen-specific tolerance, primarily by shifting the immune response from a Th2-mediated (allergic) profile to a Th1/Treg-mediated profile. This shift reduces IgE-mediated responses and increases the production of protective IgG4 antibodies and regulatory cytokines such as IL-10. It is administered via subcutaneous injection (SCIT) or sublingual (SLIT) routes. Recent research, including studies at Renji Hospital, explores its potential impact on comorbid hyperactivity symptoms in patients with respiratory allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mite allergen extract.